MEDP logo

Medpace Holdings, Inc. Stock Price

NasdaqGS:MEDP Community·US$15.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 77 Fair Values set on narratives written by author

MEDP Share Price Performance

US$532.49
189.44 (55.22%)
4.4% overvalued intrinsic discount
US$510.00
Fair Value
US$532.49
189.44 (55.22%)
4.4% overvalued intrinsic discount
US$510.00
Fair Value
Price US$532.49
AnalystHighTarget US$510.00
AnalystConsensusTarget US$423.64
AnalystLowTarget US$304.79

MEDP Community Narratives

AnalystHighTarget·Updated
Fair Value US$510 4.4% overvalued intrinsic discount

Biopharma Outsourcing And Decentralized Trials Will Redefine Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$423.64 25.7% overvalued intrinsic discount

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$305 74.6% overvalued intrinsic discount

Accelerating Costs And Funding Risk Will Undermine Biotech Stability

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent MEDP News & Updates

Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%

Aug 11
Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%

Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next

Jul 24
Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next

Medpace Holdings, Inc. Key Details

US$2.2b

Revenue

US$702.7m

Cost of Revenue

US$1.5b

Gross Profit

US$1.1b

Other Expenses

US$418.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 22, 2025
Earnings per share (EPS)
14.89
Gross Margin
68.51%
Net Profit Margin
18.74%
Debt/Equity Ratio
0%

Medpace Holdings, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Solid track record with excellent balance sheet.

2 Risks
3 Rewards

About MEDP

Founded
1992
Employees
6000
CEO
August Troendle
WebsiteView website
www.medpace.com

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 1.2%
  • 3 Months: 7.7%
  • 1 Year: 17.9%
  • Year to Date: 14.9%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. The market is up 18% over the last 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›